Therapy of diabetes mellitus and the risk of malignization

Abstract

The safety of therapy of diabetes mellitus with hyperglycemic agents is a challenging problem in modern diabetology extensively discussed in the last years, with the special emphasis being laid on the associated risk of formation and development of various neoplasms. The main forms of cancer known to occur in association with type 2 diabetes mellitus are related to obesity and insulin resistance. It suggests the important role of various factors, besides hyperinsulinism and hyperglycemia, in cancer pathogenesis. The present review is designed to analyse the influence of insulin analogs, sulphonylurea derivatives, metformin, and thiazolidindiones on the risk of malignization in the patients with diabetes mellitus.

A review of mortality in type 2 diabetes mellitus

“…Вместе с тем, наблю-дение за больными СД2 показало, что ожирение и ИМТ не были связаны со смертностью от рака [57].…”